Posted on May 18, 2010 by Sitemaster
Men with prostate cancer who are 70 years of age or older, and who are starting adjuvant androgen deprivation therapy (ADT) for locally advanced or high-risk localized prostate cancer, should receive a bone mineral density (BMD) test followed by selective bisphosphonate therapy for those with osteoporosis, according to an article in today’s issue of Annals of Internal Medicine. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, alendronate, androgen deprivation therapy, bisphosphonate, BMD, bone mineral density, test | Leave a comment »
Posted on May 13, 2009 by Sitemaster
This morning’s reports deal with:
- New Japanese guidelines on prostate cancer screening
- PCA3 — “from bench to bedside”
- Impact of hormonal therapy on bone mineral density and risk for fractures
- The initial results of the RENEW trial … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, BMD, bone mineral density, guidelines, Japan, PCA3, screening | Leave a comment »
Posted on April 10, 2009 by Sitemaster
Today’s news reports deal with:
- A comparative, single institution study of RALP vs RRP
- Bone mineral density and osteoporosis in men treated with intermittent hormone therapy
- Transdermal testosterone therapy in men with castration-resistant prostate cancer
In a separate report we have discussed the development of a pre-biopsy risk assessment nomogram that incorporates results from PCA3 testing. … READ MORE …
Filed under: Management, Treatment | Tagged: BMD, bone mineral density, intermittent hormone therapy, osterporosis, RALP, retropubic radical prostatectomy, robot-assisted laparoscopic prostatectomy, RRP, testosterone therapy | Leave a comment »
